FDA Awards Priority Review Voucher to Regeneron Pharmaceuticals for Material Threat Medical Countermeasure Product

Summary

The FDA has issued a priority review voucher to Regeneron Pharmaceuticals for its material threat medical countermeasure product INMAZEB, following a review of the product's eligibility under the Federal Food, Drug, and Cosmetic Act and the 21st Century Cures Act.